drugset / Trial / NCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799

Phase 3 Active not recruiting 360 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.

Timeline

Start
2024-07-01
Primary completion
2026-10-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 450 mg Oral
Subject Naltrexone Small molecule Other